secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-107314
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Q2 net loss widens to $30.5M on $14.8M impairment; OpRegen 36-mo data positive, cash runway into Q1 2027
--------------------------------------------------------------------------------

- Q2 2025 revenue $2.8M (+$1.4M YoY); net loss $30.5M ($0.13/sh) vs $5.8M ($0.03) YoY.
- Cash $42.3M as of June 30, 2025; expected to fund operations into Q1 2027.
- OpRegen: 36-month data shows mean BCVA +6.2 letters (n=10); +9.0 letters in extensive coverage (n=5).
- Manufacturing milestone: cGMP production demonstrated for two candidates from cell bank system, scalable to millions of doses.
- OPC1: first chronic SCI patient treated in DOSED study using novel delivery system.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000095017025107314/0000950170-25-107314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000095017025107314/lctx-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-107314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer